Have a feature idea you'd love to see implemented?
Let us know!
TGTX Tg Therapeutics Inc
Price (delayed)
$25.33
Market cap
$3.92B
P/E Ratio
37.25
Dividend/share
N/A
EPS
$0.68
Enterprise value
$3.95B
TG Therapeutics is a fully-integrated, commercial stage biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. In addition to an active
Highlights
Tg Therapeutics's EPS has surged by 154% YoY and by 134% QoQ
The company's net income has surged by 154% YoY and by 132% QoQ
TGTX's debt is up by 3.5% YoY
Key stats
What are the main financial stats of TGTX
Market
Valuations
Earnings
Shares outstanding
154.82M
Market cap
$3.92B
Enterprise value
$3.95B
Price to earnings (P/E)
37.25
Price to book (P/B)
22.05
Price to sales (P/S)
10.57
EV/EBIT
36.5
EV/EBITDA
36.45
EV/Sales
11.39
Revenue
$346.73M
EBIT
$108.19M
EBITDA
$108.35M
Free cash flow
$67.82M
Per share
Balance sheet
Liquidity
EPS
$0.68
Free cash flow per share
$0.47
Book value per share
$1.15
Revenue per share
$2.4
TBVPS
$2.77
Total assets
$401.21M
Total liabilities
$223.64M
Debt
$111.23M
Equity
$177.57M
Working capital
$280.49M
Debt to equity
0.63
Current ratio
3.58
Quick ratio
2.78
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
31.2%
Gross margin
92.8%
Net margin
27.6%
Operating margin
29.4%
Return on assets
26.7%
Return on equity
57.7%
Return on invested capital
37.8%
Return on capital employed
37%
Return on sales
31.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TGTX stock price
How has the Tg Therapeutics stock price performed over time
Intraday
-1.48%
1 week
9.51%
1 month
8.29%
1 year
242.76%
YTD
48.3%
QTD
8.29%
Financial performance
How have Tg Therapeutics's revenue and profit performed over time
Revenue
$346.73M
Gross profit
$321.62M
Operating income
$101.85M
Net income
$95.69M
Gross margin
92.8%
Net margin
27.6%
The operating income has soared by 160% YoY and by 111% from the previous quarter
The company's net income has surged by 154% YoY and by 132% QoQ
TGTX's net margin has soared by 104% YoY and by 94% QoQ
Tg Therapeutics's operating margin has surged by 104% YoY and by 76% QoQ
Growth
What is Tg Therapeutics's growth rate over time
Valuation
What is Tg Therapeutics stock price valuation
P/E
37.25
P/B
22.05
P/S
10.57
EV/EBIT
36.5
EV/EBITDA
36.45
EV/Sales
11.39
Tg Therapeutics's EPS has surged by 154% YoY and by 134% QoQ
The P/B is 66% above the last 4 quarters average of 13.5
The equity is up by 11% since the previous quarter
The P/S is 100% below the 5-year quarterly average of 5265.4 but 36% above the last 4 quarters average of 7.9
The revenue rose by 20% QoQ
Efficiency
How efficient is Tg Therapeutics business performance
TGTX's ROIC has soared by 135% YoY and by 73% QoQ
The ROA has soared by 132% YoY and by 104% from the previous quarter
The company's return on equity has surged by 119% YoY and by 84% QoQ
Tg Therapeutics's return on sales has surged by 105% YoY and by 68% QoQ
Dividends
What is TGTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TGTX.
Financial health
How did Tg Therapeutics financials performed over time
The total assets is 79% higher than the total liabilities
The total assets has soared by 82% YoY and by 7% QoQ
TGTX's current ratio is up by 25% year-on-year
TGTX's debt is 37% lower than its equity
The debt to equity has plunged by 76% YoY and by 9% from the previous quarter
The equity is up by 11% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.